Equities analysts expect Inogen Inc (NASDAQ:INGN) to post $107.00 million in sales for the current quarter, according to Zacks. Six analysts have provided estimates for Inogen’s earnings, with the lowest sales estimate coming in at $104.10 million and the highest estimate coming in at $110.68 million. Inogen posted sales of $97.24 million in the same quarter last year, which suggests a positive year over year growth rate of 10%. The company is scheduled to report its next quarterly earnings report on Tuesday, August 6th.
On average, analysts expect that Inogen will report full year sales of $408.69 million for the current financial year, with estimates ranging from $404.94 million to $411.30 million. For the next fiscal year, analysts expect that the firm will report sales of $470.24 million, with estimates ranging from $458.56 million to $482.90 million. Zacks’ sales averages are a mean average based on a survey of research analysts that follow Inogen.
Inogen (NASDAQ:INGN) last posted its quarterly earnings results on Tuesday, May 7th. The medical technology company reported $0.24 EPS for the quarter, missing analysts’ consensus estimates of $0.29 by ($0.05). Inogen had a return on equity of 15.59% and a net margin of 12.56%. The business had revenue of $90.20 million for the quarter, compared to analyst estimates of $89.69 million. During the same period last year, the firm posted $0.48 EPS. Inogen’s quarterly revenue was up 14.1% on a year-over-year basis.
INGN has been the subject of a number of recent research reports. JPMorgan Chase & Co. upped their target price on from GBX 385 ($5.03) to GBX 480 ($6.27) and gave the stock an “overweight” rating in a report on Wednesday, July 3rd. BidaskClub cut Amyris from a “hold” rating to a “sell” rating in a report on Thursday, June 27th. Needham & Company LLC raised Smart Global from a “hold” rating to a “buy” rating and set a $32.00 target price for the company in a report on Friday, June 28th. Finally, Stifel Nicolaus raised Protagonist Therapeutics from a “hold” rating to a “buy” rating and upped their target price for the stock from $11.00 to $17.00 in a report on Wednesday, May 8th. Three analysts have rated the stock with a sell rating, one has given a hold rating and three have given a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and an average price target of $117.60.
Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Marshall Wace LLP grew its position in shares of Inogen by 180.2% in the 1st quarter. Marshall Wace LLP now owns 55,580 shares of the medical technology company’s stock valued at $5,301,000 after buying an additional 35,747 shares during the last quarter. Geode Capital Management LLC grew its position in shares of Inogen by 8.6% in the 4th quarter. Geode Capital Management LLC now owns 205,160 shares of the medical technology company’s stock valued at $25,474,000 after buying an additional 16,183 shares during the last quarter. Legal & General Group Plc grew its position in shares of Inogen by 3.9% in the 4th quarter. Legal & General Group Plc now owns 17,963 shares of the medical technology company’s stock valued at $2,230,000 after buying an additional 668 shares during the last quarter. Renaissance Group LLC bought a new stake in shares of Inogen in the 1st quarter valued at about $428,000. Finally, MetLife Investment Advisors LLC grew its position in shares of Inogen by 52.3% in the 4th quarter. MetLife Investment Advisors LLC now owns 18,341 shares of the medical technology company’s stock valued at $2,277,000 after buying an additional 6,302 shares during the last quarter. Hedge funds and other institutional investors own 98.61% of the company’s stock.
INGN traded up $0.51 on Friday, reaching $62.68. The stock had a trading volume of 244,170 shares, compared to its average volume of 420,756. Inogen has a fifty-two week low of $61.35 and a fifty-two week high of $287.79. The firm’s 50-day moving average price is $66.30. The company has a debt-to-equity ratio of 0.02, a current ratio of 7.35 and a quick ratio of 6.70. The stock has a market cap of $1.36 billion, a P/E ratio of 27.25, a price-to-earnings-growth ratio of 2.46 and a beta of 1.45.
Inogen, Inc, a medical technology company, primarily develops, manufactures, and markets portable oxygen concentrators for patients, physicians and other clinicians, and third-party payors in the United States and internationally. Its oxygen concentrators are used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions.
Featured Article: Bond
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Inogen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inogen and related companies with MarketBeat.com's FREE daily email newsletter.